Thr295
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr295  -  DBNL (human)

Site Information
kQLtQPEtHFGREPA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 31085888

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:
leukemia ( 4 ) , acute myelogenous leukemia ( 4 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 3 , 4 ) , acute megakaryoblastic leukemia (M7) ( 3 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 3 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 3 ) , acute myeloblastic leukemia, without maturation (M1) ( 3 ) , B cell lymphoma ( 3 ) , non-Hodgkin's lymphoma ( 3 ) , multiple myeloma ( 3 )
Relevant cell line - cell type - tissue:

References 

1

Liu N, Sun N, Gao X, Li Z (2014) Phosphosite mapping of HIP-55 protein in mammalian cells. Int J Mol Sci 15, 4903-14
24651461   Curated Info

2

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

3

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

4

Alcolea MP, et al. (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics 11, 453-66
22547687   Curated Info